Mauricio Silva de Lima
Mauricio Silva de Lima, MD, MSc, PhD, is Head of Global Medical Affairs, OBU at Takeda. He joined the company in November of 2019 and is responsible for overseeing Takeda Oncology’s entire portfolio of products and further developing the company’s current pipeline.
Prior to joining Takeda, Dr. de Lima held several roles of increasing responsibility at Genentech and Roche, including leading the team responsible to generate new data to support the launch of Tecentriq in Europe. At Roche, Dr. de Lima was Head of Medical Affairs, Europe, where he had oversight of 28 countries and led the company’s Regional Medical Compliance Office. Dr. de Lima also served as Country Medical Director in the UK & Ireland and Brazil for Eli Lilly.
Prior to his pharmaceutical career, Dr. de Lima was an Associate Professor of Psychiatry at the School of Medicine at the Universidade Federal de Pelotas, Brazil.
Dr. de Lima received his Doctor of Medicine and Master of Science in Epidemiology from the Federal University of Pelotas, Brazil, and his PhD in Psychiatry from the Federal University of São Paulo, Brazil. In addition, Dr. de Lima received post-doctoral training in Psychiatric Epidemiology from the Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, United Kingdom.